Antibodies against the NPM-ALK fusion were first discovered in vivo in ALCL patients in the early 2000s by Pulford et al., while antibodies against ALK-WT were also found to be present in 91% of patients (25). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.